New injection aims to slow vision loss in Age-Related eye disease

NCT ID NCT06990269

Recruiting now Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether a new medication called ADX-038, given as an injection under the skin, can slow the progression of geographic atrophy—a form of age-related macular degeneration that causes permanent vision loss. About 240 participants with this condition will receive either the active drug or a placebo for 12 months to see if it helps preserve a specific layer of the retina. The main goal is to measure whether the treatment reduces the rate of damage to the light-sensitive cells in the eye.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ADARx Clinical Site
RECRUITING

Gilbert, Arizona, 85297, United States
ADARx Clinical Site
RECRUITING

Phoenix, Arizona, 85020, United States
ADARx Clinical Site
RECRUITING

Beverly Hills, California, 90211, United States
ADARx Clinical Site
NOT_YET_RECRUITING

Huntington Beach, California, 93647, United States
ADARx Clinical Site
NOT_YET_RECRUITING

Poway, California, 92064, United States
ADARx Clinical Site
ENROLLING_BY_INVITATION

Orlando, Florida, 32806, United States
ADARx Clinical Site
RECRUITING

Hagerstown, Maryland, 21740, United States
ADARx Clinical Site
RECRUITING

Erie, Pennsylvania, 16505, United States
ADARx Clinical Site
RECRUITING

McAllen, Texas, 78503, United States
ADARx Clinical Site
RECRUITING

Round Rock, Texas, 78681, United States
ADARx Clinical Site
RECRUITING

San Antonio, Texas, 78340, United States
ADARx Clinical Site
NOT_YET_RECRUITING

The Woodlands, Texas, 77384, United States
ADARx Clinical Site
RECRUITING

Albury, New South Wales, 2640, Australia
ADARx Clinical Site
RECRUITING

Parramatta, New South Wales, 2150, Australia
ADARx Clinical Site
RECRUITING

Rowville, Victoria, 3178, Australia
ADARx Clinical Site
RECRUITING

Ottawa, Ontario, K2B 7E9, Canada
ADARx Clinical Site
RECRUITING

Toronto, Ontario, M8X 2X3, Canada

Conditions

Explore the condition pages connected to this study.

GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION